Population Pharmacokinetic and Exposure-Response Modeling to Inform Upadacitinib Dose Selection in Adolescent and Adult Patients with Atopic Dermatitis.
Mohamed IsmailEva DoelgerDoerthe EckertAlan D IrvineAlvina D ChuHenrique D TeixeiraWei LiuAhmed NaderPublished in: British journal of clinical pharmacology (2023)
The results of these analyses support the dose justification for upadacitinib in adult and adolescent patients with moderate-to-severe AD.